New hosts Grace Dent and chef Anna Haugh have shaken off the show’s crusty, stale feel. They’re a real improvement on John Torode and Gregg Wallace MasterChef is back, emboldened by the strange and giddy euphoria of an enforced refresh. For nigh on 20 years, the BBC’s premier cookery contest was judged by John Torode and Gregg Wallace and was just sort of … there. Not bad, but not very exciting ei...
New hosts Grace Dent and chef Anna Haugh have shaken off the show’s crusty, stale feel. They’re a real improvement on John Torode and Gregg Wallace MasterChef is back, emboldened by the strange and giddy euphoria of an enforced refresh. For nigh on 20 years, the BBC’s premier cookery contest was judged by John Torode and Gregg Wallace and was just sort of … there. Not bad, but not very exciting either. That the hosts might have become a little crusty and stale wasn’t widely noticed or discussed. One unsavoury year of allegations, investigations and cancellations later, not one but both of the show’s long-serving overlords have abruptly departed. Yet there’s something freeing about an unplanned change and MasterChef, happily, has embraced that by hiring two relatively low-profile women to replace the old men: season 22 is brought to you by Myrtle chef patron Anna Haugh and Guardian restaurant critic Grace Dent . Continue reading...
Has artificial intelligence ascended past its status as the latest technology, and is it truly the "new Oracle of Delphi" that many are supposing? AI ethicist Carissa Véliz comes on Market Domination to talk more about her new essay published in The Economist that questions AI's ability to make predictions and whether that plays a role in rewriting certain truths and people's realities, such as wh...
Has artificial intelligence ascended past its status as the latest technology, and is it truly the "new Oracle of Delphi" that many are supposing? AI ethicist Carissa Véliz comes on Market Domination to talk more about her new essay published in The Economist that questions AI's ability to make predictions and whether that plays a role in rewriting certain truths and people's realities, such as when AI rejects a job application.
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Allied Gaming & Entertainment, Inc. (NASDAQ: AGAE) (the “Company” or “AGAE”), a global experiential entertainment company, today announced that on April 16, 2026, it received a deficiency letter (the “Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the peri...
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Allied Gaming & Entertainment, Inc. (NASDAQ: AGAE) (the “Company” or “AGAE”), a global experiential entertainment company, today announced that on April 16, 2026, it received a deficiency letter (the “Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the periodic reporting requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) (the “Rule”) because the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) was not filed with the Securities and Exchange Commission (the “SEC”) by the required due date of March 31, 2026 (or April 15, 2026 following the Form 12b-25 filed by the Company on March 31, 2026). The Letter has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq.
This AI Warning Is A Myth; The Danger Is Not... Authored by Kay Rubacek via The Epoch Times, You know this story. Drop a frog into boiling water, and it will scramble out immediately. But place that same frog in cool water, heat it slowly, and degree by degree, it will never notice the danger until it is too late. Most of us accept this without question. The problem is that the story is not true. ...
This AI Warning Is A Myth; The Danger Is Not... Authored by Kay Rubacek via The Epoch Times, You know this story. Drop a frog into boiling water, and it will scramble out immediately. But place that same frog in cool water, heat it slowly, and degree by degree, it will never notice the danger until it is too late. Most of us accept this without question. The problem is that the story is not true. It traces back to a German physiologist named Friedrich Goltz, who in 1869 conducted a series of experiments with a rather unusual purpose: to determine whether the soul resided in the brain or the spinal cord. He removed portions of a frog’s brain and observed what the animal could no longer do without it. He found that a frog without its brain would sit placidly in slowly heating water and not attempt to escape. However, a normal frog, with its brain intact, would feel the rising temperature and get out. That finding was passed around over the decades that followed, stripped of its context, and reshaped into the cautionary tale we now all repeat. later biologists confirmed the original finding: A frog in cold water will jump out before it gets too hot. The frog that stays in hot water is the one that can no longer think for itself. We have been repeating that story for more than 150 years as settled truth, because it felt right, without ever stopping to ask whether it was actually true. We accepted a false warning about the danger of not noticing gradual change, without noticing that the warning itself was false. That should give us pause on its own. But this month, it became more than an interesting historical footnote when a team of researchers from Carnegie Mellon University, the University of Oxford, MIT, and UCLA published a landmark study on how artificial intelligence (AI) is affecting human cognition. The findings are fascinating, but the metaphor they chose caught many people’s attention. They wrote of the boiling frog. Scientists studying the effects of AI on th...
MattGush/iStock via Getty Images Investment Thesis Currently, IREN Limited ( IREN ) is at a critical juncture. While market participants are concerned about the expansion of the additional share issuance limit to $6 billion, this could potentially dilute shareholders’ stakes to 37.5%. On the other hand, it's wrapping up a major business model transformation that should cement its new status as a m...
MattGush/iStock via Getty Images Investment Thesis Currently, IREN Limited ( IREN ) is at a critical juncture. While market participants are concerned about the expansion of the additional share issuance limit to $6 billion, this could potentially dilute shareholders’ stakes to 37.5%. On the other hand, it's wrapping up a major business model transformation that should cement its new status as a major player in the AI industry by aggressively scaling up its computing power to 150,000 GPUs. The goal of this article is to analyze whether raising this much additional capital is justified. Since the next quarterly report is expected to be released on May 13, most likely we will learn the reasons why management reached this decision. Thanks to calculations of its potential value, IREN remains one of the most undervalued players in the AI infrastructure sector, and as a result, my recommendation for its stock remains "Buy." Previous Arguments The arguments I presented in my previous articles about IREN explained why it is worth buying the company’s stock. The first reason is that the company is in the final stage of transforming its business model, where IREN is turning from a Bitcoin miner into a major computing power operator. Moreover, when the previous analysis was published, IREN's management announced the purchase of an additional 50,000 Nvidia ( NVDA ) GPUs, increasing the total capacity to 150,000 GPUs. Additionally, a key factor in ensuring IREN’s strategic development is its secure 4.5 GW grid connection, resolving the issue of power supply for future computing operations. That said, I also identified the potential impact of escalation in the Middle East, due to which stock prices will at the very least remain in a wide side range and exhibit extremely high volatility. Even though the stock price has risen by 33% since my last publication on IREN, it had previously fallen by up to 15% in the short term due to geopolitical events. This means that the stock’s tota...
spawns/E+ via Getty Images The Thesis: Still a Buy Opportunity In today's article, I revisit the pharma sector again with followup coverage of Amneal Pharmaceuticals, Inc. ( AMRX ), the New Jersey-based company that focuses on generics, injectables, biosimilars, and specialty branded pharmaceuticals globally. Since my first Buy rating last September, the stock is up around +32% as of this writing,...
spawns/E+ via Getty Images The Thesis: Still a Buy Opportunity In today's article, I revisit the pharma sector again with followup coverage of Amneal Pharmaceuticals, Inc. ( AMRX ), the New Jersey-based company that focuses on generics, injectables, biosimilars, and specialty branded pharmaceuticals globally. Since my first Buy rating last September, the stock is up around +32% as of this writing, confirming my bullish thesis at the time, and is also up since my December bullish rating as well, while in both cases I was impressed by its large and growing portfolio of clinical solutions. Newsworthy is that Amneal announced this week that it realized "positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the 2026 American Academy of Neurology (AAN)." My updated research today covered the following 8 rating categories in the worksheet below: Amneal - rating worksheet (author) Based on my updated research and the latest data, I continue to reaffirm a Buy rating on Amneal and view it as a growth idea. Despite some elevated risk in the balance sheet , the key drivers are macro demand for its solutions across multiple clinical areas, as well as a robust and active drug pipeline, along with strong upside forecasts and positive EPS growth estimates. Macroeconomic Factors Amneal - macro factors (author) Given the positive news mentioned earlier about its ongoing study into the benefit of its Crexont therapy in the neurology space, I think a major macro factor that could increase the role played by Amneal is in the treatment of Parkinson's disease, driven by expected growth in occurrence. For instance, a 2025 study in the Natl. Library of Medicine said, "an important challenge in neurology today is the worldwide dramatic rise in Parkinson's disease /PD incidence," while New York Presbyterian Hospital wrote in a 2025 article that "by 2050, 25.5MM people worldwide will be living with Parkinson’s disease, a 112% increase from 2021." However, I wouldn't ...
Hims & Hers Health (NYSE:HIMS) , the consumer-focused telehealth platform, closed Tuesday at $29.76, down 4.03%. The stock declined during the regular session after Amazon (NASDAQ:AMZN) launched a competing GLP-1 weight-loss program, though it has still gained 39.33% in the past week. Trading volume reached 56.7 million shares, about 50% above its three-month average of 37.8 million shares. Hims &...
Hims & Hers Health (NYSE:HIMS) , the consumer-focused telehealth platform, closed Tuesday at $29.76, down 4.03%. The stock declined during the regular session after Amazon (NASDAQ:AMZN) launched a competing GLP-1 weight-loss program, though it has still gained 39.33% in the past week. Trading volume reached 56.7 million shares, about 50% above its three-month average of 37.8 million shares. Hims & Hers Health IPO'd in 2019 and has grown 204% since going public. The S&P 500 (SNPINDEX:^GSPC) fell 0.63% to 7,064, while the Nasdaq Composite (NASDAQINDEX:^IXIC) slipped 0.59% to 24,260. Within telehealth and online health services, peers Teladoc Health (NYSE:TDOC) fell 1.64% to close at $6.00, and American Well (NYSE:AMWL) finished down 4.54% at $6.31, underscoring sentiment pressures across virtual care names. Continue reading
During Warsh's confirmation hearing, Democratic senator Elizabeth Warren expressed concerns that Federal Reserve nominee would become a 'sock puppet' for Donald Trump. Republican senator John Kennedy also asked Warsh to deny he would be the president's 'sock puppet', which he did Continue reading...
During Warsh's confirmation hearing, Democratic senator Elizabeth Warren expressed concerns that Federal Reserve nominee would become a 'sock puppet' for Donald Trump. Republican senator John Kennedy also asked Warsh to deny he would be the president's 'sock puppet', which he did Continue reading...
Tech companies keep announcing job cuts, and experts don’t expect that to stop anytime soon. Reuters reported on Saturday that Meta Platforms is planning to conduct an initial wave of layoffs on May 20, with more coming later this year. The report, citing sources familiar with the matter, said that Meta plans to lay off about 10% of its global workforce, or close to 8,000 employees, in that initia...
Tech companies keep announcing job cuts, and experts don’t expect that to stop anytime soon. Reuters reported on Saturday that Meta Platforms is planning to conduct an initial wave of layoffs on May 20, with more coming later this year. The report, citing sources familiar with the matter, said that Meta plans to lay off about 10% of its global workforce, or close to 8,000 employees, in that initial round.
Dragos Condrea/iStock via Getty Images Voyager Therapeutics ( VYGR ) announced on Tuesday in an SEC Form 8-K filing that its CFO, Nathan Jorgensen, has resigned, effective May 8, 2026, to take up a new opportunity. The Board has appointed Robin Swartz (current COO & CBO) as the new Principal Financial Officer and Treasurer, effective immediately upon transition, ensuring continuity in finance lead...
Dragos Condrea/iStock via Getty Images Voyager Therapeutics ( VYGR ) announced on Tuesday in an SEC Form 8-K filing that its CFO, Nathan Jorgensen, has resigned, effective May 8, 2026, to take up a new opportunity. The Board has appointed Robin Swartz (current COO & CBO) as the new Principal Financial Officer and Treasurer, effective immediately upon transition, ensuring continuity in finance leadership. Adding to the leadership reshuffle, Amy Quinlan has been named Principal Accounting Officer, strengthening the company’s accounting oversight. Following the news, the stock closed ~2.60% lower at ~$4.12. More on Voyager Therapeutics Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026 Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript Seeking Alpha’s Quant Rating on Voyager Therapeutics Historical earnings data for Voyager Therapeutics
NVIDIA (NASDAQ:NVDA) presents a compelling bull case at $199. The AI infrastructure buildout driving its business shows no sign of slowing, and the stock trades well below its 52-week high of $212.19 despite accelerating fundamentals. NVIDIA designs the GPUs and networking systems powering modern AI infrastructure. Its data center business dominates revenue as hyperscalers, governments, and ... NV...
NVIDIA (NASDAQ:NVDA) presents a compelling bull case at $199. The AI infrastructure buildout driving its business shows no sign of slowing, and the stock trades well below its 52-week high of $212.19 despite accelerating fundamentals. NVIDIA designs the GPUs and networking systems powering modern AI infrastructure. Its data center business dominates revenue as hyperscalers, governments, and ... NVIDIA at $199: Buy, Sell or Hold
Some investors might choose to stay out of the famously volatile biotech industry right now, given that equities are already facing plenty of uncertainty that has rocked the market. However, even in this environment, there are excellent biotech stocks to consider buying. These may or may not escape the ongoing volatility, but in the long run, they could deliver excellent returns. For those with $2...
Some investors might choose to stay out of the famously volatile biotech industry right now, given that equities are already facing plenty of uncertainty that has rocked the market. However, even in this environment, there are excellent biotech stocks to consider buying. These may or may not escape the ongoing volatility, but in the long run, they could deliver excellent returns. For those with $2,000 to spare (make sure you have enough money put away for a rainy day first), here are two biotech stocks to consider: Moderna (NASDAQ: MRNA) and Regeneron (NASDAQ: REGN) . Image source: Getty Images. Moderna could deliver superior returns over the long run thanks to its mRNA vaccine platform. Here are two reasons why. First, mRNA vaccines can be designed more quickly than conventional vaccines. Many traditional vaccines work by injecting a weakened virus into the patient and letting the body's immune response essentially have a practice run at it, so that when it comes in contact with the real thing, it's ready. However, this method requires several time-consuming steps, including growing large quantities of the virus and safely inactivating it. Continue reading
Olemedia GitLab (GLTB) shares rose more than 6% in extended trading on Tuesday after the DevOps company announced it has deepened its collaboration with Amazon Web Services ( AMZN ). As part of the collaboration, customers will be able to use GitLab Duo Agent Platform inference through Amazon Bedrock models that they are already running on their AWS accounts, GitLab said in a statement . The compa...
Olemedia GitLab (GLTB) shares rose more than 6% in extended trading on Tuesday after the DevOps company announced it has deepened its collaboration with Amazon Web Services ( AMZN ). As part of the collaboration, customers will be able to use GitLab Duo Agent Platform inference through Amazon Bedrock models that they are already running on their AWS accounts, GitLab said in a statement . The company added that GitLab credits can be purchased in the AWS Marketplace and count towards their existing AWS spending commitments. In addition, GitLab's “bring your own model” feature for certain customers will allow their teams to be connected directly to Amazon Bedrock. “For AWS customers, this integration makes that possible,” Manav Khurana, chief product and marketing officer at GitLab, explained. “GitLab Duo Agent Platform runs through Amazon Bedrock accounts they already manage, governed by policies they already enforce, and funded by commitments they've already made. AI adoption scales when it fits into decisions already made, not when it asks teams to make new ones.” “GitLab Duo Agent Platform on Amazon Bedrock means customers can deploy agentic AI for software development without standing up new infrastructure, negotiating new contracts, or rethinking their security posture,” said Rahul Pathak, vice president, data & AI GTM at AWS in a statement. “It runs inside their existing AWS environment — same IAM policies, same compliance controls, same spending commitments. That’s how AI adoption should work.” More on GitLab, Amazon Amazon Could Re-Rate After Earnings Again (Preview) Amazon: The Anthropic Trade You're Not Making Amazon: My Top 8 Reasons To Buy Amazon One Medical launches GLP-1 management program Anthropic's $100B commitment to Amazon benefits Marvell and Astera Labs: analysts
May WTI crude oil (CLK26 ) on Tuesday closed up +2.52 (+2.81%), and May RBOB gasoline (RBK26 ) closed up +0.0930 (+2.98%). Crude oil and gasoline prices recovered from early losses on Tuesday and moved sharply higher as Iran has yet to confirm its attendance at further talks in Pakistan...
May WTI crude oil (CLK26 ) on Tuesday closed up +2.52 (+2.81%), and May RBOB gasoline (RBK26 ) closed up +0.0930 (+2.98%). Crude oil and gasoline prices recovered from early losses on Tuesday and moved sharply higher as Iran has yet to confirm its attendance at further talks in Pakistan...
May Nymex natural gas (NGK26 ) on Tuesday closed up +0.008 (+0.30%). Nat-gas prices on Tuesday erased early losses and moved higher as a rally in crude oil prices, driven by the continued closure of the Strait of Hormuz, sparked short-covering in nat-gas futures. Nat-gas prices initially moved lower on...
May Nymex natural gas (NGK26 ) on Tuesday closed up +0.008 (+0.30%). Nat-gas prices on Tuesday erased early losses and moved higher as a rally in crude oil prices, driven by the continued closure of the Strait of Hormuz, sparked short-covering in nat-gas futures. Nat-gas prices initially moved lower on...
The critically acclaimed second season of Apple TV's dystopian sci-fi drama Silo ended on one heck of a cliffhanger, with at least one major character's fate unclear. The streamer just released the first teaser for S3, in which events from the first two seasons rewind to give us the briefest glimpse of the lushly green, seemingly idyllic early days of the silo community, centuries before. (Spoiler...
The critically acclaimed second season of Apple TV's dystopian sci-fi drama Silo ended on one heck of a cliffhanger, with at least one major character's fate unclear. The streamer just released the first teaser for S3, in which events from the first two seasons rewind to give us the briefest glimpse of the lushly green, seemingly idyllic early days of the silo community, centuries before. (Spoilers for the first two seasons below.) As previously reported , Silo is based on the trilogy by novelist Hugh Howey. It's set in a self-sustaining underground city inhabited by a community whose recorded history only goes back 140 years. Outside is a toxic hellscape that is only visible on big screens in the silo’s topmost level. Inside, 10,000 people live together under a pact: Anyone who says they want to “go out” is immediately granted that wish—cast outside in an environment suit on a one-way trip to clean the cameras. But those who make that choice die soon after because of the toxic environment. Read full article Comments
SoundHound AI (NASDAQ:SOUN) , a provider of voice AI solutions for the automotive, TV, IoT, and customer service industries, closed at $7.85, down 5.65%. Shares declined after news of an all-stock LivePerson acquisition. Investors will be watching the shareholder dilution from the deal and for execution on omnichannel AI growth targets. Trading volume reached 54.2 million shares, about 107% above ...
SoundHound AI (NASDAQ:SOUN) , a provider of voice AI solutions for the automotive, TV, IoT, and customer service industries, closed at $7.85, down 5.65%. Shares declined after news of an all-stock LivePerson acquisition. Investors will be watching the shareholder dilution from the deal and for execution on omnichannel AI growth targets. Trading volume reached 54.2 million shares, about 107% above its three-month average of 26.2 million shares. SoundHound AI IPO'd in 2022 and has grown 5% since going public. The S&P 500 slipped 0.65% to 7,063, while the Nasdaq Composite fell 0.59% to finish at 24,260. Among software (application) peers, C3.ai closed at $9.20 (-1.97%) and BigBear.ai ended at $3.79 (-1.30%), reflecting cautious sentiment around AI software names. SoundHound AI made a big move today, acquiring conversational AI peer LivePerson and its Conversational Cloud for roughly $250 million, including LivePerson’s debt balance. The complementary deal forms a powerhouse in the conversational AI niche, serving 25 of the Fortune 100 and 12 of the top 15 global banks. Continue reading
HeliRy/E+ via Getty Images DHT Holdings ( DHT ) and Frontline ( FRO ) were downgraded at Evercore ISI on Tuesday to In-Line from Outperform, while Nordic American Tanker ( NAT ) was cut to Underperform from In-Line, noting spot rates reside at record levels, but "the parabolic move over the last two months has been driven by an anomalous factor, namely the closing of the Strait of Hormuz." As inve...
HeliRy/E+ via Getty Images DHT Holdings ( DHT ) and Frontline ( FRO ) were downgraded at Evercore ISI on Tuesday to In-Line from Outperform, while Nordic American Tanker ( NAT ) was cut to Underperform from In-Line, noting spot rates reside at record levels, but "the parabolic move over the last two months has been driven by an anomalous factor, namely the closing of the Strait of Hormuz." As investors consider the next move in rates, asset values, and earnings, "a thesis regarding an eventual resolution to Iranian hostilities points to an unfavorable rate of change, with only 'when' and 'how much' in question," Evercore analyst Jonathan Chappell wrote. The lack of follow-through in tanker stocks since the war began and rates spiked "highlights a reluctance to further push premiums, and line of sight on reversion is likely to lead to profit-taking," the analyst said. VLCC orders set a record in Q1, but Chappell sees demand growth threatened by higher oil prices, rendering greater potential downside risk to utilization when the Middle East war ends. ETFs: ( BWET ), ( BOAT ) More on DHT Holdings and Frontline DHT Holdings: Solid Fundamentals And Strategic Vessel Management Justify Valuation DHT: BW Overhang Almost Gone, Q2 Dividend Could Top 20% The Shape Of Oil/Energy Shipping: Looking At Frontline